NO314405B1 - Farmasöytisk aktive forbindelser og liposomer og anvendelse derav - Google Patents

Farmasöytisk aktive forbindelser og liposomer og anvendelse derav Download PDF

Info

Publication number: NO314405B1
Authority: NO; Norway
Prior art keywords: group; carbons; alkyl; formula; chain
Prior art date: 1994-02-02

Application number

NO19963224A

Other languages

English (en)

Norwegian (no)

Other versions

NO963224D0 (no

NO963224L (no

Inventor

Yong-Wei Pei

Eric Mayhew

Imran Ahmad

Andrew Stuart Janoff

Original Assignee

Liposome Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-02

Filing date

1996-08-01

Publication date

2003-03-17

1996-08-01 Application filed by Liposome Co Inc filed Critical Liposome Co Inc

1996-08-01 Publication of NO963224D0 publication Critical patent/NO963224D0/no

1996-09-27 Publication of NO963224L publication Critical patent/NO963224L/no

2003-03-17 Publication of NO314405B1 publication Critical patent/NO314405B1/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 61
239000002502 liposome Substances 0.000 title claims description 92
125000000217 alkyl group Chemical group 0.000 claims abstract description 74
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 40
230000002401 inhibitory effect Effects 0.000 claims abstract description 31
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 20
125000003342 alkenyl group Chemical group 0.000 claims abstract description 18
125000000304 alkynyl group Chemical group 0.000 claims abstract description 18
125000001931 aliphatic group Chemical group 0.000 claims abstract description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 12
150000002632 lipids Chemical class 0.000 claims description 41
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
241001465754 Metazoa Species 0.000 claims description 27
239000012867 bioactive agent Substances 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 17
239000000460 chlorine Substances 0.000 claims description 15
201000011510 cancer Diseases 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 14
239000013589 supplement Substances 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 12
YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 10
229950004354 phosphorylcholine Drugs 0.000 claims description 10
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
229910052801 chlorine Inorganic materials 0.000 claims description 8
229910052731 fluorine Inorganic materials 0.000 claims description 8
239000011737 fluorine Substances 0.000 claims description 8
229910007161 Si(CH3)3 Inorganic materials 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims 1
229940088594 vitamin Drugs 0.000 claims 1
229930003231 vitamin Natural products 0.000 claims 1
235000013343 vitamin Nutrition 0.000 claims 1
150000003722 vitamin derivatives Chemical class 0.000 claims 1
238000006243 chemical reaction Methods 0.000 abstract description 33
229940106189 ceramide Drugs 0.000 description 66
210000004027 cell Anatomy 0.000 description 57
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 44
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 44
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 44
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 43
239000000203 mixture Substances 0.000 description 40
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
NPRJSFWNFTXXQC-QFWQFVLDSA-N N-(hexanoyl)sphing-4-enine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCC NPRJSFWNFTXXQC-QFWQFVLDSA-N 0.000 description 24
238000000034 method Methods 0.000 description 20
150000001783 ceramides Chemical class 0.000 description 18
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 17
238000009472 formulation Methods 0.000 description 17
239000011647 vitamin D3 Substances 0.000 description 17
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 17
235000005282 vitamin D3 Nutrition 0.000 description 17
229940021056 vitamin d3 Drugs 0.000 description 17
235000012000 cholesterol Nutrition 0.000 description 15
230000012010 growth Effects 0.000 description 15
230000006907 apoptotic process Effects 0.000 description 14
230000000694 effects Effects 0.000 description 12
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
230000001093 anti-cancer Effects 0.000 description 11
BLTCBVOJNNKFKC-QUDYQQOWSA-N N-acetylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O BLTCBVOJNNKFKC-QUDYQQOWSA-N 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
239000003937 drug carrier Substances 0.000 description 10
150000003410 sphingosines Chemical class 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
230000030833 cell death Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
239000010432 diamond Substances 0.000 description 7
-1 sphingolipid compounds Chemical class 0.000 description 7
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 7
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
125000002252 acyl group Chemical group 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
210000000865 mononuclear phagocyte system Anatomy 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
238000012746 preparative thin layer chromatography Methods 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
102000003390 tumor necrosis factor Human genes 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000037396 body weight Effects 0.000 description 5
229910003460 diamond Inorganic materials 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
KKEGLSGSXXNARS-UMBAGBCYSA-N (E,8R,9R)-8-amino-7,9-dihydroxytetracos-10-en-6-one Chemical compound C(CCCCC)(=O)C(O)[C@H](N)[C@H](O)C=CCCCCCCCCCCCCC KKEGLSGSXXNARS-UMBAGBCYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 4
229930182558 Sterol Natural products 0.000 description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
239000012736 aqueous medium Substances 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
239000012043 crude product Substances 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
150000003432 sterols Chemical class 0.000 description 4
235000003702 sterols Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000232 Lipid Bilayer Substances 0.000 description 3
241000714177 Murine leukemia virus Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
229940034982 antineoplastic agent Drugs 0.000 description 3
230000001640 apoptogenic effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000033077 cellular process Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000018044 dehydration Effects 0.000 description 3
238000006297 dehydration reaction Methods 0.000 description 3
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
239000003810 Jones reagent Substances 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 2
108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
229940009456 adriamycin Drugs 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
238000001816 cooling Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
125000001183 hydrocarbyl group Chemical group 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
230000014207 opsonization Effects 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
208000016691 refractory malignant neoplasm Diseases 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000002002 slurry Substances 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
150000003408 sphingolipids Chemical class 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 1
CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical class C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
206010020843 Hyperthermia Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
229910010084 LiAlH4 Inorganic materials 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
108010047956 Nucleosomes Proteins 0.000 description 1
BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical compound OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
239000000370 acceptor Substances 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000003817 anthracycline antibiotic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
230000008011 embryonic death Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
125000005313 fatty acid group Chemical group 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
230000036031 hyperthermia Effects 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000003801 milling Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
230000008450 motivation Effects 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
210000001623 nucleosome Anatomy 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical group CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000002459 polyene antibiotic agent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
238000010186 staining Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
230000008685 targeting Effects 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000002691 unilamellar liposome Substances 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Manufacturing Of Micro-Capsules (AREA)

NO19963224A 1994-02-02 1996-08-01 Farmasöytisk aktive forbindelser og liposomer og anvendelse derav NO314405B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19029594A	1994-02-02	1994-02-02
PCT/US1995/001490 WO1995021175A1 (fr)	1994-02-02	1995-02-02	Composes et liposomes pharmaceutiquement actifs, et procedes pour leur utilisation

Publications (3)

Publication Number	Publication Date
NO963224D0 NO963224D0 (no)	1996-08-01
NO963224L NO963224L (no)	1996-09-27
NO314405B1 true NO314405B1 (no)	2003-03-17

Family

ID=22700754

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19963224A NO314405B1 (no)	1994-02-02	1996-08-01	Farmasöytisk aktive forbindelser og liposomer og anvendelse derav

Country Status (14)

Country	Link
US (3)	US5631394A (fr)
EP (2)	EP1008342A3 (fr)
JP (1)	JPH09508900A (fr)
AT (1)	ATE195944T1 (fr)
AU (1)	AU691886B2 (fr)
CA (1)	CA2182485A1 (fr)
DE (1)	DE69518627T2 (fr)
DK (1)	DK0742789T3 (fr)
ES (1)	ES2149350T3 (fr)
FI (1)	FI116620B (fr)
GR (1)	GR3034521T3 (fr)
NO (1)	NO314405B1 (fr)
PT (1)	PT742789E (fr)
WO (1)	WO1995021175A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6255336B1 (en)	1995-09-20	2001-07-03	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) *	1995-09-20	1999-06-29	The Regents Of The University Of Michigan	Amino ceramide--like compounds and therapeutic methods of use
US5834016A (en) *	1996-04-04	1998-11-10	Cilag Ag	Liposome-based topical vitamin D formulation
US6274309B1 (en) *	1996-07-26	2001-08-14	Richard Kolesnick	Method for the modulation of acid-sphingomyelinase-related apoptosis
CN1055640C (zh) *	1996-11-29	2000-08-23	沃维汉	人降钙素基因相关肽脂质体组合物及其制法
US6982142B2 (en)	1997-12-01	2006-01-03	John Wayne Cancer Institute	Methods for screening therapeutically effective agents
ATE334686T1 (de) *	1999-03-25	2006-08-15	Ct Molecular Med & Immunology	Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapie
US7683044B2 (en)	1999-03-25	2010-03-23	Center For Molecular Medicine And Immunology	Sphingomyelin therapy of autoimmune disease
US7820718B1 (en) *	1999-04-07	2010-10-26	Roger Williams Hospital	Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
TW502133B (en)	1999-06-10	2002-09-11	Wako Pure Chem Ind Ltd	Resist composition, agent and method for reducing substrate dependence thereof
US6682545B1 (en) *	1999-10-06	2004-01-27	The Penn State Research Foundation	System and device for preventing restenosis in body vessels
WO2001038295A1 (fr) *	1999-11-24	2001-05-31	Taisho Pharmaceutical Co.,Ltd.	Derives de sphingosine
US6410597B1 (en) *	2000-02-25	2002-06-25	Virginia Commonwealth University	Hydroxyalkyl amide analogs of ceramide
WO2002051439A2 (fr)	2000-12-22	2002-07-04	Medlyte, Inc.	Compositions et procedes destines au traitement et a la prevention de troubles et de maladies cardio-vasculaires, et a l'identification d'agents therapeutiques correspondants
PT2266968E (pt) *	2001-07-16	2013-02-25	Genzyme Corp	Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
EP1287815A1 (fr) *	2001-08-31	2003-03-05	Cosmoferm B.V.	Utilisation d'une base sphingoide pour inhiber l'activité de la céramidase
US20060217560A1 (en) *	2002-04-29	2006-09-28	Shayman James A	Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) *	2002-04-29	2005-07-12	Genzyme Corporation	Amino ceramide-like compounds and therapeutic methods of use
US20070031480A1 (en) *	2003-03-07	2007-02-08	Lawrence Mayer	Enhanced delivery of sphingolipids
EP1610763A2 (fr) *	2003-03-31	2006-01-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Ensembles de lipides contenant des amphiphiles de formation non liposomique
JP5107573B2 (ja)	2003-04-25	2012-12-26	ザペンステイトリサーチファウンデーション	増殖抑制性脂質由来生物活性化合物の全身送達方法およびシステム
US7906122B2 (en)	2003-06-18	2011-03-15	Yissum Research Development Company Of The Hebrew University Of Jersusalem	Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
AU2004246904B2 (en)	2003-06-18	2010-02-04	Biolab Ltd.	Sphingolipids polyalkylamine conjugates for use in transfection
US7794713B2 (en)	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2008519840A (ja)	2004-11-10	2008-06-12	ジェンザイム・コーポレイション	糖尿病の処置方法
CN101102752A (zh) *	2004-11-15	2008-01-09	耶路撒冷希伯来大学伊萨姆研发公司	联合优选为神经酰胺与细胞毒性药物的联合疗法
JP4791082B2 (ja) *	2005-05-30	2011-10-12	株式会社クラレ	リポソームおよびそれを含む皮膚外用剤
WO2007044748A2 (fr) *	2005-10-11	2007-04-19	University Of Pittsburgh	Liposomes de sphingomyeline pour le traitement de troubles de vessie hyperactive
WO2007134086A2 (fr) *	2006-05-09	2007-11-22	Genzyme Corporation	Méthodes pour traiter une maladie de foie adipeux
US9274130B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Prevention and treatment of pain using antibodies to lysophosphatidic acid
US20080138334A1 (en)	2006-05-31	2008-06-12	Sabbadini Roger A	Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US7862812B2 (en)	2006-05-31	2011-01-04	Lpath, Inc.	Methods for decreasing immune response and treating immune conditions
US9274129B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Methods and reagents for detecting bioactive lipids
US8796429B2 (en)	2006-05-31	2014-08-05	Lpath, Inc.	Bioactive lipid derivatives, and methods of making and using same
CA2667706A1 (fr)	2006-10-27	2008-05-08	Lpath, Inc.	Compositions et procedes pour traiter des maladies et des troubles oculaires
DK2087002T3 (da)	2006-10-27	2014-10-27	Lpath Inc	Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
EP2594562B1 (fr)	2007-05-31	2016-07-20	Genzyme Corporation	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
KR101640263B1 (ko)	2007-10-05	2016-07-15	젠자임 코포레이션	세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
WO2009132082A2 (fr) *	2008-04-22	2009-10-29	Medical College Of Georgia Research Institute, Inc.	Compositions immunogènes contenant des céramides et leurs méthodes d’utilisation
JP2011529500A (ja)	2008-07-28	2011-12-08	ジェンザイムコーポレーション	虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
US8309593B2 (en)	2008-10-03	2012-11-13	Genzyme Corporation	2-acylaminopropoanol-type glucosylceramide synthase inhibitors
SG10201407881WA (en)	2009-11-27	2015-01-29	Genzyme Corp	An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US9207232B2 (en) *	2011-08-15	2015-12-08	National University Corporation Chiba University	Ceramide derivative and Golgi apparatus-labeling fluorescent probe using same
KR102423002B1 (ko) *	2021-02-17	2022-07-21	주식회사 엘씨에스바이오텍	신규 세라마이드, 그의 제조방법 및 그의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522803A (en) *	1983-02-04	1985-06-11	The Liposome Company, Inc.	Stable plurilamellar vesicles, their preparation and use
US5169637A (en) *	1983-03-24	1992-12-08	The Liposome Company, Inc.	Stable plurilamellar vesicles
US5030453A (en) *	1983-03-24	1991-07-09	The Liposome Company, Inc.	Stable plurilamellar vesicles
US4588578A (en) *	1983-08-08	1986-05-13	The Liposome Company, Inc.	Lipid vesicles prepared in a monophase
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes
US5008050A (en) *	1984-06-20	1991-04-16	The Liposome Company, Inc.	Extrusion technique for producing unilamellar vesicles
US5077056A (en) *	1984-08-08	1991-12-31	The Liposome Company, Inc.	Encapsulation of antineoplastic agents in liposomes
US5059421A (en) *	1985-07-26	1991-10-22	The Liposome Company, Inc.	Preparation of targeted liposome systems of a defined size distribution
US4975282A (en) *	1985-06-26	1990-12-04	The Liposome Company, Inc.	Multilamellar liposomes having improved trapping efficiencies
JP2588729B2 (ja) *	1987-10-05	1997-03-12	塩野義製薬株式会社	スフィンゴシン誘導体
FR2637598B1 (fr) *	1988-10-06	1991-10-11	Agronomique Inst Nat Rech	Nouveaux sphingophospholipides a inositol, leur obtention, et leur application comme inducteurs de resistance a diverses maladies cryptogamiques chez les vegetaux
US5100662A (en) *	1989-08-23	1992-03-31	The Liposome Company, Inc.	Steroidal liposomes exhibiting enhanced stability
DE4021082C2 (de) *	1990-07-03	1995-08-17	Hans Dr Lautenschlaeger	Hautbehandlungsmittel mit hohen Lipidgehalten unter Verwendung eines Bilayer enthaltenden Systems, Salzen organischer Säuren, Alkohol und Stabilisator
JPH05508863A (ja) *	1990-08-13	1993-12-09	デューク・ユニバーシティ	セラミドを使用して細胞分裂を誘導する方法
GB9022921D0 (en) *	1990-10-22	1990-12-05	Unilever Plc	Cosmetic composition
GB9100816D0 (en) *	1991-01-15	1991-02-27	Unilever Plc	Cosmetic composition
DE4201461A1 (de) *	1992-01-21	1993-07-22	Mueller Schulte Detlef Dr	Mittel fuer die selektive tumortherapie auf der basis ferromagnetischer partikel - verfahren zu ihrer herstellung und verwendung

1995
- 1995-02-02 EP EP00102434A patent/EP1008342A3/fr not_active Withdrawn
- 1995-02-02 EP EP95910923A patent/EP0742789B1/fr not_active Expired - Lifetime
- 1995-02-02 WO PCT/US1995/001490 patent/WO1995021175A1/fr not_active Ceased
- 1995-02-02 DE DE69518627T patent/DE69518627T2/de not_active Expired - Fee Related
- 1995-02-02 DK DK95910923T patent/DK0742789T3/da active
- 1995-02-02 ES ES95910923T patent/ES2149350T3/es not_active Expired - Lifetime
- 1995-02-02 PT PT95910923T patent/PT742789E/pt unknown
- 1995-02-02 US US08/383,291 patent/US5631394A/en not_active Expired - Fee Related
- 1995-02-02 JP JP7520799A patent/JPH09508900A/ja not_active Ceased
- 1995-02-02 AT AT95910923T patent/ATE195944T1/de not_active IP Right Cessation
- 1995-02-02 CA CA002182485A patent/CA2182485A1/fr not_active Abandoned
- 1995-02-02 AU AU18712/95A patent/AU691886B2/en not_active Ceased
- 1995-10-19 US US08/547,688 patent/US5677337A/en not_active Expired - Lifetime
- 1995-10-19 US US08/545,164 patent/US5681589A/en not_active Expired - Lifetime
1996
- 1996-08-01 FI FI963045A patent/FI116620B/fi not_active IP Right Cessation
- 1996-08-01 NO NO19963224A patent/NO314405B1/no unknown
2000
- 2000-09-29 GR GR20000402211T patent/GR3034521T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK0742789T3 (da)	2000-11-13
CA2182485A1 (fr)	1995-08-10
FI963045L (fi)	1996-08-01
DE69518627T2 (de)	2001-01-11
GR3034521T3 (en)	2000-12-29
WO1995021175A1 (fr)	1995-08-10
US5677337A (en)	1997-10-14
PT742789E (pt)	2000-12-29
EP1008342A3 (fr)	2004-12-29
EP0742789B1 (fr)	2000-08-30
US5631394A (en)	1997-05-20
DE69518627D1 (de)	2000-10-05
FI116620B (fi)	2006-01-13
EP1008342A2 (fr)	2000-06-14
ATE195944T1 (de)	2000-09-15
NO963224D0 (no)	1996-08-01
AU1871295A (en)	1995-08-21
EP0742789A1 (fr)	1996-11-20
AU691886B2 (en)	1998-05-28
ES2149350T3 (es)	2000-11-01
US5681589A (en)	1997-10-28
NO963224L (no)	1996-09-27
JPH09508900A (ja)	1997-09-09
FI963045A0 (fi)	1996-08-01

Publication	Publication Date	Title
EP0742789B1 (fr)	2000-08-30	Composes et liposomes pharmaceutiquement actifs, et procedes pour leur utilisation
KR100386002B1 (ko)	2003-10-10	소수성탁산유도체
EP0274174A1 (fr)	1988-07-13	Composition de dérivé anthraquinone-liposome et sa préparation
US20090041835A1 (en)	2009-02-12	Method of inhibiting leakage of drug encapsulated in liposomes
NO316206B1 (no)	2003-12-29	Eterlipid-liposomer og farmasöytiske sammensetninger av disse
WO1994026254A1 (fr)	1994-11-24	Incorporation de taxol dans des liposomes et des gels
EP1426044B1 (fr)	2006-02-08	Utilisation d'esters de L-carnitine ou de L-carnitine d'alcanoyl comme lipides cationiques pour l'administration intracellulaire de composés thérapeutiques
JPWO1991010431A1 (ja)	1992-01-09	脂肪乳剤
US5304380A (en)	1994-04-19	Glucosamine derivative and liposome containing the same as membrane constituent
EP1254143B1 (fr)	2004-09-29	Systemes d'administration de medicaments a base de lipides renfermant des derives degradables de la phospholipase a2 et utilisations therapeutiques
US6667053B1 (en)	2003-12-23	D and L etherlipid stereoisomers and liposomes
US6017557A (en)	2000-01-25	Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof
US12208138B2 (en)	2025-01-28	Radiation-triggered liposomes
US20080193509A1 (en)	2008-08-14	Liposome Preparation Containing Slightly Water-Soluble Camptothecin
US7449197B2 (en)	2008-11-11	Liposome formulation of 6,9-bis[(2-aminoethyl)-amino]benzo[g]isoquinoline-5, 10-dione dimaleate
CA2647779A1 (fr)	2007-09-27	Systemes d'administration de medicaments a base de lipides contenant des lipides degradables par la phospholipase a2 qui produisent une reaction de cyclisation intramoleculaire lors de l'hydrolyse
HK1025512A (en)	2000-11-17	Pharmaceutically active compounds and liposomes, and methods of use thereof
EP4527843A1 (fr)	2025-03-26	Phosphatidyloligoglycerol stereoisomerique
WO1991010431A1 (fr)	1991-07-25	Emulsion grasse
JPWO2001000173A1 (ja)	2003-01-21	リポソームに内包された薬物の漏出抑制方法